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Introduction: A chronic shortage of organs remains the main factor limiting organ transplantation. Many countries
have explored the option of uncontrolled donation after circulatory death (uDCD) in order to expand the donor
pool. Little is known regarding the variability of practices and outcomes between existing protocols. This systematic
review addresses this knowledge gap informing policy makers, researchers, and clinicians for future protocol
implementation.
Methods: We searched MEDLINE, EMBASE, and Google Scholar electronic databases from 2005 to March 2015 as
well as the reference lists of selected studies, abstracts, unpublished reports, personal libraries, professional organization
reports, and government agency statements on uDCD. We contacted leading authors and organizations to request
their protocols and guidelines. Two reviewers extracted main variables. In studies reporting transplant outcomes, we
added type, quantity, quality of organs procured, and complications reported. Internal validity and the quality of the
studies reporting outcomes were assessed, as were the methodological rigour and transparency in which a guideline
was developed. The review was included in the international prospective register of systematic reviews
(Prospero, CRD42014015258).
Results: Six guidelines and 18 outcome studies were analysed. The six guidelines are based on limited evidence and
major differences exist between them at each step of the uDCD process. The outcome studies report good results for
kidney, liver, and lung transplantation with high discard rates for livers.
Conclusions: Despite procedural, medical, economic, legal, and ethical challenges, the uDCD strategy is a viable
option for increasing the organ donation pool. Variations in practice and heterogeneity of outcomes preclude a
meta-analysis and prevented the linking of outcomes to specific uDCD protocols. Further standardization of protocols
and outcomes is required, as is further research into the role of extracorporeal resuscitation and other novel therapies
for treatment of some refractory cardiac arrest. It is essential to ensure the maintenance of trust in uDCD programs by
health professionals and the public.* Correspondence: iviortega@gmail.com
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A chronic shortage of organs remains the main factor
limiting organ transplantation for patients with end-stage
organ failure. Although organ transplants save thousands
of lives and transform the quality of life of thousands
more, many people will die or remain on renal replace-
ment therapy because the organ supply falls drastically
short of demand. In Europe, nearly 99,000 patients were
waiting for an organ in 2013 whilst the number of
deceased donors has remained stable at approximately
9900 [1]. This is also the case in the US, where 30,000
patients were on waiting lists and the number of deceased
donors was 8268 [1]. In Canada, the situation is equally
concerning. At the end of 2013, 4433 patients were on the
waiting lists and only 553 actual deceased donors were
obtained that year [2]. The mismatch between supply
and demand for organs has led policy makers and health
institutions to develop new strategies aimed at expanding
the organ donor pool. As a result, many countries
worldwide have explored the option of donation after
circulatory death (DCD).
The DCD procedure seeks to obtain solid organs from
patients previously declared dead following the cessation
of their circulatory and respiratory functions. There are
two distinct methods: controlled DCD (cDCD) and
uncontrolled DCD (uDCD). The cDCD occurs after
an anticipated in-hospital cardiac arrest, generally but
not exclusively in intensive care unit patients who have
suffered a catastrophic brain injury and for whom a deci-
sion has been made to withdraw life-sustaining therapies
(WLST). In this scenario, consent for cDCD is obtained,
WLST occurs and a variable amount of time later, death is
declared, and organs are procured. The uDCD is initiated
following an unexpected, and usually out-of-hospital,
refractory cardiac arrest. After resuscitation attempts
are judged futile, interventions—ongoing cardiac com-
pressions and mechanical ventilation—are initiated to
preserve organs for donation. The diagnosis of death
may occur after resuscitation is terminated on scene
or after arrival to the hospital. There is a “no touch”
period after which death is determined and organ
preservation may be restarted. After hospital arrival,
cannulation and organ preservation with extracorporeal
perfusion or in situ cooling begin. Consent requirements
for donation and organ preservation vary by region and
may occur before or after cannulation.
Protocols for uDCD have already been implemented in
Spain, France, Italy, the UK, and The Netherlands [3].
Protocols have also been developed in other countries,
such as Belgium, Switzerland, and Austria, and in Saint
Petersburg (Russia) and in New York City [4]. These
international experiences have demonstrated that uDCD
is an effective way to increase the availability of solid
organs for transplantation [5]. Although uDCD appearsto have promising results in terms of graft survival, it raises
several medical, ethical, legal, economic, and logistic chal-
lenges at the intersection of cardiac arrest, resuscitation,
organ donation, and organ preservation after declaring
death [6, 7]. Little is known regarding the variability of
practices between existing protocols [8] and less still
regarding the comparative effectiveness of implementing a
particular protocol [9].
The purpose of this systematic review is to address
this knowledge gap by compiling and analyzing the
defining elements and reported transplant outcomes of
the currently active protocols and guidelines for uDCD.
To the best of our knowledge, no systematic review
has been conducted to specifically evaluate and com-
pare the practices and outcomes of uDCD protocols,
nor has any evaluation of the quality of guidelines
for implementing such protocols been performed.
This review will inform uDCD protocol and practice
development, which has applicability to policy makers,
researchers, and clinicians to assist in future protocol
implementation.
Methods
Design of the study and search strategy
We conducted a systematic review of the literature in
accordance with reviews in health care from the Center
for Reviews and Dissemination, from the University of York
[10]. We used a modified PICOTS format: Population:
potential uDCD candidates; Intervention: active protocols
for uDCD; Control: not applicable; Outcomes: in terms of
(a) define elements of international practices on protocols
for uDCD and, when reported (b) grafts obtained or trans-
planted (or both), as well as graft or patient survival and
complications (or both); Time: 2005 to March 2015; and
Setting: any organization that has produced a recommenda-
tion or protocol for uDCD.
We developed a comprehensive search strategy with
the help of a qualified librarian. We searched MEDLINE,
EMBASE, and Google Scholar electronic databases from
2005 to March 2015. The search included English, French,
Italian, and Spanish and was limited to human studies. We
manually searched the reference lists of selected studies
and the grey literature for unpublished reports, personal
libraries, professional organization, and government agency
statements on uDCD. We also contacted leading authors
and organizations in the field of uDCD to request their
protocols and guidelines.
Eligibility criteria
Our inclusion criteria for review were any kind of report
proposing a clinical procedure for uDCD endorsed by
a government agency, professional organization, pro-
fessional society, or regional health-care organization.
We excluded any editorials, letters, abstracts, or personal
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tioned organizations.
Study selection
Two trained reviewers (IO-D and LH) screened all cita-
tions. We retrieved the full texts of selected citations
and independently reviewed them to assess study eli-
gibility. Disagreements were resolved by consensus
or with the intervention of a third expert reviewer (SDS).
We used EndNote manager software (EndNote X7.1
version by Thomson Reuters) to manage the collection
of publications. Figure 1 describes the study selection
process.
Data extraction and quality assessment
Two reviewers (IO-D and LH) extracted data. We
created an Excel (Excel version 2013 by Microsoft
Office, Microsoft Corporation, Redmond, WA, USA)
data collection tool that was piloted in a sample from
the list of included studies. The final version of the
spreadsheet included the following variables: name of
the authors, country, language, setting, year, type of
study and method, eligibility criteria for population, inter-
vention and timelines during process, organ preservationFig. 1 Flow chart of study selection processdetails, death determination characteristics, type and time
of consent, and any ethical, legal, and logistic issues
described. For the studies reporting transplant out-
comes, we added type, quantity, quality of organs
procured, and complications reported. Internal validity
of the studies was assessed independently by two re-
viewers (IO-D and LH). The quality of the studies
reporting outcomes was assessed by using the Downs
and Black scale [11]. The Appraisal of Guidelines for
Research and Evaluation (AGREE) Instrument version
II [12] was used to assess the methodological rigour
and transparency of guidelines. Up to three reviewers
assessed each guideline.
Data synthesis
We anticipated heterogeneity in selected studies and
guidelines. Variability was apparent in eligibility criteria,
organs obtained, timelines along the ischaemia process,
determination of circulatory death practices, ischaemia
definition, and techniques for organ preservation.
Therefore, pooling of study data was not feasible and
a meta-analysis was not possible. Rather, data analysis
consisted of a tabulation of characteristics from studies
and guidelines.
Ortega-Deballon et al. Critical Care  (2015) 19:268 Page 4 of 15Review end points
This systematic review aimed to address the following
question: What are the defining elements and reported
outcomes of currently active protocols and recommen-
dations for uDCD?
Results
After launching the search strategy (Fig. 1), we obtained
114 potentially relevant citations, in addition to 18 from
grey literature, resulting in a total of 132 references for
further review. Of these, 113 were excluded after a first
screening for the following reasons: not relevant (n = 42);
editorials, surveys, or opinions (n = 32); referring to results
from cDCD (n = 19); duplicated data (n = 16); and case
reports or abstracts (n = 4). The resulting 19 references
were selected for further review, and five new citations
were included from their reference lists. Therefore, a total
of 24 references were screened after acquiring the full-text
version. Following the full-text review, six citations were
excluded because the study population was duplicated
while two other citations from reference lists were
included. During the second screening, we contacted
agencies of different countries involved in implementation
of protocols for uDCD and received three more guidelines
in response to our request. Thus, a final total of 23
references—17 studies [13–29], five guidelines [4, 30–33],
and one article [34] that included both a full guideline
description and transplant outcomes—was included.
Thus, for the purpose of this review, six guidelines and 18
outcome studies were analysed.Fig. 2 Timelines and clinical pathway in the process of uncontrolled donatMain characteristics of guidelines
Figure 2 is an illustrative example of the uDCD procedure
timelines and clinical pathway described within the guide-
lines. Timelines begin with a cardiac arrest, followed by ini-
tiation of cardiopulmonary resuscitation (CPR), termination
of CPR, continuation of organ-preserving interventions,
diagnosis of death, and cannulation for organ preservation.
As will be further described below, there are variable
periods of no-flow and low-flow states that may impact on
pre- and post-mortem ischemic organ injury and there is
variability in the timing of, and requirement for consent for,
donation or organ preservation or both.
In our review, we included six guidelines from as
many countries. The main characteristics are described
in Table 1 (“Guidelines” section) and summarized here.
Cardiac arrest location and uncontrolled donation after
circulatory death donor definition
All of the guidelines describe potential uDCD donors as
those patients suffering an out-of hospital refractory cardiac
arrest after failed resuscitation in the field. The guidelines
from France, Italy, and Switzerland also consider in-hospital
patients as potential donors. Age limits for donors most
commonly included adults and older teenagers, but chil-
dren were also eligible in some regions of Spain (Table 1).
Geographic implementation and organs procured
In the case of France and Spain, national recommenda-
tions do exist for uDCD. The uDCD strategy has been
implemented in Spain since 1995 with the pioneeringion after circulatory death (DCD). CPR cardiopulmonary resuscitation
Table 1 Characteristics of included guidelines and eligible outcome studies
Guidelines (n = 6)
National/Regional Guideline Country; region (year) Language Population targeted Lo on of cardiac arrest Organ(s)
FRANCE (2007) [30] French Adult O f hospital and in hospital Kidney and liver
ITALY; Pavia (2011) [34] English Adult and children (≥15 years) O f hospital and in hospital Kidney
SWITZERLAND (2011) [32] French Adult and children (≥16 years) O f hospital and in hospital Kidney
US; New York City (2011) [4] English Adult and children O f hospital Kidney and
liver (phased in)
SPAIN [31];
Alicante (2012) Spanish Adult and children (≥14 years) O f hospital Kidney, liver, and lung
Barcelona (2012) Adult and children (≥14 years) Kidney and liver
Castilla La Mancha (2012) Adult and children (≥7 years) Kidney, liver, and lung
Granada (2012) Adult and children (≥7 years) Kidney, liver, and lung
Galicia (2012) Adult and children (≥14 years) Kidney and liver
Madrid City and Region (2012) Adult and children Kidney, liver, and lung
UK; Scotland (2013) [33] English Adult and children (≥16 years) O f hospital Kidney, Liver and lungs
Eligible outcome studies (n = 18)
Study/Country, Region Study design Population studied Lo on of cardiac arrest Organ(s)
Gámez 2005 [13]/Spain, Madrid Case series Adult O f hospital Lung
Gagandeep 2006 [14]/USA, Nationwide Database review comparison to DBD and cDCD Adult and children in pital Kidney
Sánchez-Fructuoso 2006 [15]/Spain, Madrid Retrospective cohort Adult O f hospital and in hospital Kidney
Fondevila 2007 [16]/Spain, Barcelona Retrospective cohort with Matched DBD controls Age not specified O f hospital Liver
Suárez 2008 [17]/Spain, La Coruna Retrospective cohort compared to HBD Adult O f hospital and in hospital Liver
Fieux 2009 [18]/France, Paris Prospective cohort Adult O f hospital Kidney
Gómez Gutiérrez 2009 [19]/Spain, La Coruña and Madrid Case series Adult O f hospital Liver
Jiménez-Galanes 2009 [20]/Spain, Madrid Prospective case Control matched to DBD Adult O f hospital Liver
Ribalta 2009 [29]/Spain, Cataluña Retrospective cohort Adult and children O f hospital Kidney and liver
Mateos-Rodríguez 2010 [21]/Spain, Madrid Retrospective cohort Adult and children O f hospital Kidney, liver, and lungs
Mateos-Rodríguez 2010 [22]/Spain, Madrid Retrospective cohort Adult O f hospital Kidney






























Table 1 Characteristics of included guidelines and eligible outcome studies (Continued)
Hoogland 2011 [23]/The Netherlands, Maastricht Retrospective cohort compared with cDCD Adult Out of hospital Kidney
Rodríguez 2011 [24]/Spain, Madrid and Santander Retrospective cohort Adult and children Out of hospital Lungs
Fondevila 2012 [25]/Spain, Barcelona Retrospective cohort Adult Out of Hospital Liver
Gómez-de-Antonio 2012 [26]/Spain, Madrid Prospective cohort Adult Out of hospital Lung
Hanf 2012 [27]/France, Lyon Prospective cohort compared with ECD and SPK Adult Out of hospital Kidney
Reznick 2013 [28]/Russia, St Petersburg Retrospective cohort Adult In hospital Kidney
Extended criteria donors (ECDs) were all donors at least 60 years old and those 50–59 years old with at least two of the other three conditions (cerebrovascular cause of death, renal insufficiency with serum creatinine
less than or equal to 1.5 mg/dl, and hypertension)
DBD donation after brain death, cDCD controlled donation after circulatory death, HBD heart beating donors, SPK simultaneous non-sensitized kidney pancreas transplanted patients that received kidneys from
optimal donors
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not published until 2012. In France, guidelines were
published in 2007 and only after this were several uDCD
programs implemented. In the case of Italy, the protocol
has also achieved results but is operating only in the region
of Pavia. The protocol of New York City, though running,
has not reported any transplant outcomes. In Scotland,
a standard operating procedure is being piloted at
Edinburgh. Spanish recommendations include seven
uDCD protocols operating in six different regions,
including Madrid which has two programs. At present,
the guidelines from both Spain and the UK include proce-
dures for recovering kidneys, livers, and lungs. France is
recovering kidneys and livers. In Italy, kidneys are being
procured. Switzerland, New York City, and Scotland
consider only kidney procurement. A summary of the
specific details of the uDCD process contained within the
guidelines is included in Table 2 (“Guidelines” section)
and this process is further described here.
Death declaration and time restrictions
For the studies that provided a definition of refractory car-
diac arrest, it is defined as 30 minutes of failed resuscita-
tion. Death determination in France and Switzerland
obliges the absence of circulation, spontaneous ventilation,
and the performance of a rapid neurologic assessment to
confirm the absence of consciousness, spontaneous motor
activity, and brainstem reflexes. A rapid neurological test-
ing is also performed in the New York City protocol in the
prehospital setting. Scotland determines death in the emer-
gency department after 5 minutes of absent cardiopulmo-
nary activity defined by the absence of respiratory effort
and no electrical activity on the electrocardiogram, no car-
diac movement on focused echocardiography, or no pres-
sure wave visible on the arterial line tracing. A “no-touch
period”, defined as a hands-off interval, during which no
interventions to the body are allowed, is required for de-
claring death. This period follows the decision to stop re-
suscitation or organ preservation attempts and varies
widely between protocols, ranging from 5 to 20 minutes.
There is also wide variation with respect to the maximum
allowable times for each of the following periods: cardiac
arrest prior to CPR (range of 15 to 30 minutes), CPR to
cannulation (range of 90 to 120 minutes), and cannulation
to organ procurement (range of 120 to 360 minutes).
Organ preservation
All six guidelines recommend femoral arterial and venous
cannulation and extracorporeal membrane oxygenation
(ECMO) (re-initiation of circulation with an oxygenated
solution). Spain recommends both normothermic and
hypothermic conditions, whereas France recommends
hypothermic ECMO. Scotland, Italy, and New York City
use normothermic ECMO. In Spain and France, dependingon center experience, the organ preservation techniques
may also include in situ cooling with flushing of cold pres-
ervation fluids into the abdominal cavity and/or pleural
spaces. Switzerland considers in situ cooling preservation
and normothermic ECMO. The ex vivo renal perfusion
machine is being used in Spain, France, and Italy and was
proposed in Scotland and New York City. Spain has
recently expanded the use of ex vivo organ perfusion for
lung preservation in some centers.
Ethical, legal, and logistic issues
To a variable extent, all of the included guidelines address
a number of ethical, legal, and logistic issues associated
with uDCD. Table 2 describes various issues in guidelines,
including information provided to next of kin in the field
(4/6), organ preservation initiated in the ambulance
during transport (4/6), consent for cannulation and
procurement (5/6), objective of inserting an intra-aortic
balloon (3/6), health providers’ attitudes and beliefs
(4/6), role of ECMO organ-preserving versus lifesaving
technique (1/6), and cost-effectiveness considerations (4/6).
Guideline appraisal
To assess the rigour of clinical practice guideline develop-
ment, the six documents from countries with national or
regional guidelines were evaluated. Additional file 1 con-
tains an appraisal of each of the guidelines. In accordance
with the AGREE II appraisal process, scaled scores for each
of six different domains are presented. After a global inter-
pretation of the quality scores, we observed that lower
scores for all the guidelines assessed were in the domains
of “Rigour of development”, “Applicability”, and “Editorial
independence”. The higher-quality scores were obtained in
the domains of “Scope and purpose” and “Clarity of
presentation”. In regard to the domain of “Stakeholder
involvement”, the quality scores were low or fair for all
assessed guidelines, with the exception of the New York
City protocol, which obtained the highest score.
Main characteristics and protocol details of studies
reporting transplant outcomes
Our review included 18 studies that reported outcomes
for recipients of organs recovered by uDCD protocols.
The main characteristics of the studies are described
in Table 1 (“Eligible outcome studies” section) and are
summarized here.
Types of studies and organs procured
The included studies were carried out at centres in Spain,
France, the US, The Netherlands, and Russia. There were
no randomized controlled trials; all studies were observa-
tional in nature. Three studies were prospective cohorts
[18, 26, 27], one study was a prospective case control [20],
one was a retrospective cohort with matched controls [16],
Table 2 Summary of specific details of included guidelines and eligible outcome studies
Death declaration Time restrictions
Definition of refractory
cardiac arrest




with no CPR (min)
Max time - CPR to
cannulation (min)






Guidelines (n = 6)
France (2007) [30] 30 ACLS 5 30 90 mCPR 120 aCPR 120 mCPR 150 aCPR 180 ISC 240 ECMO
Italy; Pavia (2011) [34] NS 20 15 110 125 360
Switzerland (2011) [32] 20 10 30 120 150 180
US; New York City (2011) [4] 30 NS NS 120 NS 240
Spain; Alicante, Barcelona, Castilla La Mancha, Granada,
Galicia, Madrid City and Region (2012) [31]
Failed CPR 5 15 A, C, Gr, M 20 Ga 30 B 120 150 120 ISC 240–360 ECMO
UK; Scotland (2013) [33] Failed CPR 5 15 105 120 NS
Eligible outcome studies (n = 18)
Gámez 2005 [13]/Spain, Madrid 30 5 15 105 120 240
Gagandeep 2006 [14]/USA, Nationwide NS NS NS NS NS NS
Sánchez-Fructuoso 2006 [15]/Spain, Madrid 30 5 15 105 120 240
Fondevila 2007 [16]/Spain, Barcelona NS 5 15 135 150 240
Suárez 2008 [17]/Spain, La Coruna NS 5 15 105 120 240
Fieux 2009 [18]/France, Paris 30 ACLS 5 30 90 mCPR 120 aCPR 120 mCPR 150 aCPR 180 ISC 240 ECMO
Gómez Gutierrez 2009 [19]/Spain, La Coruña
and Madrid
Failed CPR 5 NS NS 120 130
Jiménez-Galanes 2009 [20]/Spain, Madrid Failed CPR 5 15 135 150 240-270
Ribalta 2009 [29]/Spain, Cataluña Failed CPR 5 30 120 150 NS
Mateos-Rodríguez 2010 [21]/Spain, Madrid Failed CPR 5 15 105 120 NS
Mateos-Rodríguez 2010 [22]/Spain, Madrid 30 5 15 105 120 240
Geraci and Sepe 2011 [34]/Italy, Pavia NS 20 15 110 125 360
Hoogland 2011 [23]/The Netherlands, Maastricht NS 5 NS 90 NS NS
Rodríguez 2011 [24]/Spain, Madrid and Santander NS 5 10 110 120 240
Fondevila 2012 [25]/Spain, Barcelona 20 5 15 150 165 240
Gomez-de-Antonio 2012 [26]/Spain, Madrid NS 5 15 105 120 240
Hanf 2012 [27]/France, Lyon 30 5 30 90 mCPR 120 aCPR 120 mCPR 150 aCPR 180











Table 2 Summary of specific details of included guidelines and eligible outcome studies (Continued)






































N N Y Y Y Y Y Y N Y N N Y
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Y Y N Y N N N N N N N N N
N Y N N Y Y Y OPV Y Y Y Y Y Y
Y Y A B C Gr
M
Y M Y A Ga
Gr
Y B M Y Y Y Y Y N Y y
Y Y N N Y N N Y Y Y N Y Y
Y N Y Y N N N N N N N N Y
NS NS NS NS NS NS NS NS NS NS NS Y Y
Y N Y Y Y N N N N N N N N
Y Y N N Y N N Y N N N N N
Y Y Y N N N N N N N N N N
N N Y Y Y Y Y Y N Y N N Y
Y Y N Y N N N N N Y N N Y
Y Y N N NS N N Y N N N N Y
Y NS NS NS Y N N N N N N N Y
Y Y NS N NS N N N N N Y N Y
Y Y N NS NS N N N N N Y N Y
N Y N N Y N Y Y N N N Y Y
Y N N Y Y N N Y N N Y N Y
Y N N Y Y N N N N N N N N
Y Y N N N N N Y N N N Y N
Y N N Y Y
after2009
N N N N N N N N
NS Y N Y Y N N N N N N N N
Y Y N N NS N N Y N N Y N Y
CPR cardiopulmonary resuscitation, n-ECMO normothermic extracorporeal membrane oxygenation, h-ECMO hypothermic extracorporeal membrane oxygenation, ECMO extracorporeal membrane oxygenation, ACLS advanced
cardiac life support, mCPR manual cardiopulmonary resuscitation, aCPR automated cardiopulmonary resuscitation, ISC in situ cooling, OPV organ preservation vehicle, N the procedure is not used or the issue is not discussed,
Y the procedure is used or issue is discussed, NS not specified (no information specified in guideline or study), A Alicante, C Castilla La Mancha, Gr Granada, M Madrid City and Region, Ga Galicia, B Barcelona
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cDCD or donation after brain death [14, 17, 23], eight were
retrospective cohorts [15, 21, 22, 24, 25, 28, 29, 34], and
two were case series [13, 19]. The organs procured were
kidneys (10 studies), livers (seven studies), and lungs
(four studies). Although one study reported results for all
three organs [21] and another for two organs [29], most
studies were focused on single-organ procurement.
Age of donors and location of cardiac arrest
Potential donors were mostly young adults (between 18
and 65 years), and only a few studies included pediatric
populations [14, 21, 24, 29]. Trends to limit the upper
age when liver or lungs are procured do exist [13, 16, 17,
19, 20, 24–26]. The potential donors were recruited
mainly outside the hospital (OHCA) in Europe, although
some studies from Spain [15, 17] and one from Italy [34]
also enrolled potential donors after presenting in-hospital
cardiac arrest (IHCA). Outcome studies from the US [14]
and Russia [28] restricted uDCD donors to IHCA. A
summary of the specific details of the uDCD process
for the studies reporting outcomes is included in Table 2
(“Eligible Outcome Studies” section) and this process is
further described here.
Refractory cardiac arrest to death declaration
Based on the illustrative uDCD clinical pathway timelines
in Fig. 2, permissible timelines are reviewed in Table 2.
Maximum times limits were reported for each of the
following intervals: cardiac arrest prior to CPR (no-flow,
range of 10 to 30 minutes), CPR to cannulation (low flow,
range of 90 to 150 minutes for OHCA), and cannulation
to organ procurement (range of 130 to 270 minutes).
There is wide variability among studies with respect to the
criteria for determining when a sudden cardiac arrest is
considered to be refractory to resuscitation. Most reports
refer to failed CPR without defining CPR duration. In the
studies in which it was specified, death determination was
based only on circulatory criteria, with the exception of the
two French studies [18, 27] in which an additional neuro-
logic screening was performed according to legal require-
ments. In the Russian single-center experience [28], always
after an IHCA, resuscitation attempts were stopped after
being judged futile and then a “no-touch period”, of up to
60 minutes, occurred while waiting for the organ pro-
curement team to arrive. Based on these findings, the
so-called warm ischemic time (WIT), resulting from the
addition of “no-flow” and “low-flow” periods until the be-
ginning of in-hospital preservation techniques that were
instituted, ranged from 120 to 150 minutes.
Organ preservation
Three different organ-preserving options were described:
in situ cooling preservation of abdominal organs or lungsand hypothermic (h-ECMO) and normothermic (n-ECMO)
extracorporeal membrane oxygenation. Both h-ECMO
and n-ECMO recirculate a preservation liquid and
oxygenated blood through the body of the donor.
The insertion of an inflated intra-aortic balloon was
widely used when the ECMO technique was deployed
to isolate the perfusion of abdominal organs and to
avoid the reperfusion of the heart and brain [16, 17,
21, 22, 25]. A trend in the use of the ex vivo perfusion
machine was observed [15, 16, 18, 23, 24, 29]. The time of
organ preservation using the above-described tech-
niques (so-called “cold ischemic time”) varied from 180 to
270 minutes.
Ethical, legal, and logistic issues
Heterogeneity in practice was evidenced in terms of the
requirement and timing of consent for both beginning
preservation and the procurement of organs as well as
for who the consent is obtained from (donor next of kin or
recipient of an organ procured from uDCD donor or both).
In addition, a number of ethical, legal, and logistic issues
derived from daily practice were discussed by the authors.
These included the type of information provided to next of
kin in the field, consent requirements (if any), stated goals
of intervention for pre-hospital and in-hospital organ
preservation, and the potential conflict of interest between
lifesaving and organ-preserving ECMO.
Appraisal of outcome study quality
Additional file 2 contains the quality assessment of the
outcome studies. All studies were observational in nature
and therefore by design were generally of low quality.
Most presented high risk of confounding, risk of bias, and
threats to external validity.
Transplant outcomes
We reviewed the outcomes from 10 studies procuring
kidneys, seven procuring livers and four where lungs were
obtained (Table 3). Larger sample sizes were derived from
the Spanish experience [15, 17, 19–22, 24–26] and
the two reported multicenter retrospective cohort
reviews [14, 23]. Kidneys transplanted from uDCD
donors demonstrated fair [14, 15, 23, 28] or poor [18, 27]
early results in terms of delayed graft function,
although all studies reported good results for graft
and patient survival in the short and medium terms.
Liver transplants from uDCD donors reported a low
percentage of primary non-function and acceptable
graft and patient survivals, but in all cases this was at the
expense of discarding a high proportion of potential
livers [16, 17, 19–21, 25, 29]. Although the experience
with transplanted lungs is still limited, there are sig-
nificant rates of acute rejection and primary non-
function of the graft as well as medical complications
Table 3 Outcomes of included studies (n = 18)
Outcome studies Time period Total donors Total recipients Outcomes
by organ type n n
Lung – 3 studies
• 1 case series [13] 2002 to 2009 66 67 Time to extubation: 21 hours–144 days
• 1 retrospective cohort [24] Hospital stay: 20–59 days
Primary graft dysfunction: 17–46.9 %• 1 prospective cohort [26]
1-year patient survival: 68 %
3-year patient survival 57 %
5-year patient survival 51 %
No comparisons were made to outcomes using cDCD or DBD donors.
Kidney – 8 studies
• 1 database review [14] 1981 to 2011 750 629a Primary graft non-function: 0–22 %
Delayed graft function: 51–92 %• 5 retrospective cohort [15, 22, 23, 28, 34]
1-year graft survival: 87.4–100 %• 2 prospective cohort [18, 27]
3-year graft survival: 100 %
5-year graft survival: 63–82.1 %
10-year graft survival: 50 %
1-year patient survival: 95–100 %
3-year patient survival: 100 %
5-year patient survival: 78–90 %
10-year patient survival: 61 %
Three studies compared outcomes with DBD donors; two studies reported no significant differences in primary graft non-function, graft survival,
and patient survival, but delayed graft function was significantly higher for recipients of uDCD kidneys.
One study compared outcomes with cDCD donors and reported no difference in any of the outcomes.
Liver – 5 studies
• 1 case series [19] 1994 to 2010 122 122 Primary graft non-function: 10–18 %
• 3 retrospective cohort [16, 17, 25] 1-year graft survival: 50–80 %
• 1 prospective case–control [20] 5-year graft survival: 49 %
1-year patient survival: 70–85.5 %
5-year patient survival: 62 %
Four studies compared outcomes with DBD donors and reported no significant differences in 1-year graft and patient survival and 5-year patient
survival, but primary graft non-function was significantly higher and 5-year graft survival was significantly lower for recipients of uDCD livers
Kidney and liver – 1 study
• 1 retrospective cohort [29] 2008 34 K 4 L NR No outcomes reported
Kidney, liver, and lung – 1 study
• 1 retrospective cohort [21] 2005 to 2008 82 158 K 16 L 13 LG Primary graft non-function of kidneys: 9 %
Rejection rate of kidneys: 9 %
Acute rejection rate of liver: 25 %
No outcomes reported for lungs
cDCD controlled donation after circulatory of death, DBD donation after brain death, uDCD uncontrolled donation after circulatory death, K kidney, L liver, NR not
reported, LG lung
aGangandeep did not report number of recipients and Fieux 2009 reported outcomes for 24/31 recipients. (Complete outcome data can be found in
Additional file 3)
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and patient survival are improving considerably based
on the results of the most recent study [26].
(Complete outcome data can be found in Additional file 3).Discussion
uDCD is a complex and labour-intensive process. Although
there has been an extended experience with uDCD in
Spain, pioneering the strategy with seven programs, the
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opment and thus critical analysis and summative evaluation
are difficult. The purpose of this review was to assemble
and evaluate the uDCD guidelines and outcomes in order
to inform the medical, ethical, legal, and logistic issues to
be addressed in the ongoing development of future
protocols and health policy. We summarize two
sources to inform practice: international guidelines
and transplant outcome reports. We have created an
illustration of the clinical pathway and timelines that
describe the process (Fig. 2).
Several countries in Europe (France, Italy, Scotland,
Spain, and Switzerland) have guidelines for uDCD. In
North America, after several failed attempts to implement
this strategy [35], New York City is the only area to have
developed uDCD guidelines. Assessment of uDCD guide-
lines by using the AGREE II appraisal process revealed
that although most of the guidelines scored well in rela-
tion to the domains of “Scope and purpose”, “Stakeholder
involvement”, and “Clarity of presentation”, improvements
were necessary in the domains of “Rigour of development”
and “Editorial independence”.
We evidenced wide variability of recommendations
regarding the definitions of and time limits associated
with death declaration as well as “no flow” and “low
flow” periods. The practices associated with ante-mortem
or post-mortem intervention, the logistic pathway, and
the organ-preserving techniques used throughout process
were also inconsistent.
The heterogeneity of the outcome studies prevents any
meaningful comparison between programs. With these
limitations in mind, it appears that uDCD can provide
viable, good-quality organs. There will need to be better
consistency and clarity in the reporting of outcomes,
standardized definitions of each step of the ischaemia
process and higher homogeneity of follow-up times for
both graft and patient survival.
All of the reviewed guidelines included specific
concerns with ethical, legal, and logistic implications.
Many authors [5–7, 9, 22, 23, 31, 35–53] have pointed out
that protocols for uDCD entail specific challenges. These
issues, if unresolved, may hinder further worldwide
development of uDCD strategy [9]. Specifically, authors
have expressed concerns with respect to irreversibility of
cardiac arrest, cannulation of the potential donor for the
purpose of organ preservation without prior consent,
possible re-establishment of oxygenated reperfusion of the
brain after declaring death, and potential conflict of inter-
ests between resuscitation attempts and organ-preserving
measures. Some authors have recommended a clarifica-
tion of the abovementioned concerns before the further
implementation of protocols for uDCD [6, 37, 41, 42, 44],
whereas others have called for a moratoria in currently
active protocols [43]. A bundle of novel therapies are inevolution for treating selected patients suffering from a re-
fractory cardiac arrest (e.g., extracorporeal resuscitation
and support, percutaneous coronary intervention, intra-
aortic balloon pump, thrombolysis, and mild hypothermia,
all deployed during or early after resuscitation attempts).
Results, where this approach has been already imple-
mented, are encouraging in terms of long-term sur-
vival with good neurologic recovery in some of these
patients [54–63]. The availability of these interven-
tions poses potential conflicts of interest between life-
saving and organ-preserving strategies [41, 42, 46].
Some of us [7, 51, 64, 65], and many other authors
[38–42, 46, 48, 49, 53, 66], have suggested different
approaches, seeking to save lives, when still feasible,
but providing also the option of organ donation when all
lifesaving clinical efforts have been exhausted. Thus, a
joint venture between clinical and research communities
in transplantation and resuscitation should combine both
strategies in order to improve resuscitation outcomes
while expanding uDCD.
This systematic review has several limitations. Although
organisations provided us with draft protocols or guidelines
for uDCD, only fully developed guidelines were included in
the review, reducing the overall scope of guidelines to
assess. The AGREE II appraisal process was used to assess
the quality of guideline development. Though well
supported, this tool is not the only accepted method
for this purpose. The lack of homogenous data from
the studies reporting transplant outcomes also precluded
a meta-analysis and prevented the linking of outcomes to
specific protocols used for the uDCD process.
Conclusions
To the best of our knowledge, this is the first systematic
review to compare the worldwide variability in practices,
protocols, and transplant outcomes for uDCD in order
to inform future protocol development and health
policy. We conclude that uDCD is a viable option for
increasing the organ donation pool. Despite variations in
practice and heterogeneity of outcomes, uDCD yields
success in kidney, liver, and lung transplantation. The
implementation of uDCD has significant medical and
logistic complexities, and international leaders should be
recognized for their efforts. Depending on regional
perspectives, there are a number of procedural, medical,
legal, and ethical challenges that include definitions of
refractory cardiac arrest, time limits for organ ischaemia,
timing and type of consent required, determination of
death, and organ-preserving interventions. Given the
limited levels of evidence on which the current guide-
lines are based as well as the lack of both standardized
definitions and processes between guidelines, it is not
possible to recommend one protocol over another.
Further standardization of guidelines and outcomes is
Ortega-Deballon et al. Critical Care  (2015) 19:268 Page 13 of 15required. Further research is required into the role of
extracorporeal resuscitation and other novel therapies
for treatment of refractory cardiac arrest of cardiac
origin. The maintenance of trust by health professionals
and by the public is recognized as a key point for the
long-term success and widespread implementation of the
valuable and promising uDCD strategy.
Key messages
 The uDCD is a viable option for increasing the
organ donation pool, yielding success in kidney,
liver, and lung transplantation.
 Depending on regional perspectives, there are a
number of procedural, medical, legal, and ethical
challenges such as definitions of refractory cardiac
arrest, time limits for organ ischaemia, timing and
type of consent required, determination of death,
and organ-preserving interventions.
 Current guidelines for uDCD are based on limited
levels of evidence
 Standardization of definitions and processes would
avoid the current existing variability in practices and
heterogeneity of outcomes
 The maintenance of trust by health professionals
and by the public is a key point for the long-term
success and widespread implementation of the
uDCD strategy.
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